14-15 November 2018
|European Case Law Identifier:||ECLI:EP:BA:2016:T159911.20160301|
|Date of decision:||01 March 2016|
|Case number:||T 1599/11|
|IPC class:||C07H 21/04
|Language of proceedings:||EN|
|Download and more information:||
|Title of application:||Amylase variants|
|Applicant name:||Novozymes A/S|
|Opponent name:||Danisco US Inc.|
|Relevant legal provisions:||
|Keywords:||Basis of decision - text or agreement to text withdrawn by patent proprietor
Basis of decision - patent revoked
Summary of Facts and Submissions
I. The patent proprietor and the opponent have lodged appeals against the interlocutory decision of the opposition division maintaining European patent No. 1 538 155 in amended form.
II. The parties were summoned to oral proceedings scheduled to take place on 16 February 2016.
III. With letter dated 8 February 2016, the patent proprietor stated that it did no longer approve the text in which the patent had been granted and that it would not submit an amended text.
IV. The board cancelled the oral proceedings.
Reasons for the Decision
1. Pursuant to Article 113(2) EPC the EPO shall examine, and decide upon the European patent only in the text submitted to it, or agreed by the proprietor of the patent.
2. Such an agreement cannot be deemed to exist if the patent proprietor - as in the present case - expressly states that it no longer approves the text of the patent as granted and declares that he will not be submitting an amended text. Rather, it has to be inferred from such statement, that the patent proprietor wishes to prevent any text whatever of the patent from being maintained.
3. It is established case law that in the present circumstances, the proceedings are to be terminated by a decision ordering revocation of the patent, without going into the substantive issues (T 73/84, OJ EPO 1985, 241).
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is revoked.